Patents by Inventor Steven A. Rosenberg

Steven A. Rosenberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INTRACELLULAR GENOMIC TRANSPLANT AND METHODS OF THERAPY
    Publication number: 20200306310
    Abstract: Genetically modified compositions, such as non-viral vectors and T cells, for treating cancer are disclosed. Also disclosed are the methods of making and using the genetically modified compositions in treating cancer.
    Type: Application
    Filed: June 12, 2020
    Publication date: October 1, 2020
    Inventors: Branden Moriarity, Beau Webber, Modassir Choudhry, Steven A. Rosenberg, Douglas C. Palmer, Nicholas P. Restifo
  • INTRACELLULAR GENOMIC TRANSPLANT AND METHODS OF THERAPY
    Publication number: 20200306309
    Abstract: Genetically modified compositions, such as non-viral vectors and T cells, for treating cancer are disclosed. Also disclosed are the methods of making and using the genetically modified compositions in treating cancer.
    Type: Application
    Filed: June 12, 2020
    Publication date: October 1, 2020
    Inventors: Branden Moriarity, Beau Webber, David Largaespada, Modassir Choudhry, Steven A. Rosenberg
  • TUMOR INFILTRATING LYMPHOCYTES AND METHODS OF THERAPY
    Publication number: 20200289571
    Abstract: Genetically modified compositions, such as non-viral vectors and tumor infiltrating lymphocytes, for the treatment of gastrointestinal cancer are disclosed. Disclosed are methods of utilizing a CRISPR system to generate genetically modified compositions. Also disclosed are the methods of making and using the genetically modified compositions for the treatment of gastrointestinal cancer.
    Type: Application
    Filed: May 28, 2020
    Publication date: September 17, 2020
    Inventors: Branden Moriarity, Beau Webber, Modassir Choudhry, Steven A. Rosenberg, Douglas C. Palmer, Nicholas P. Restifo
  • TUMOR INFILTRATING LYMPHOCYTES AND METHODS OF THERAPY
    Publication number: 20200289570
    Abstract: Genetically modified compositions, such as non-viral vectors and tumor infiltrating lymphocytes, for the treatment of gastrointestinal cancer are disclosed. Disclosed are methods of utilizing a CRISPR system to generate genetically modified compositions. Also disclosed are the methods of making and using the genetically modified compositions for the treatment of gastrointestinal cancer.
    Type: Application
    Filed: May 28, 2020
    Publication date: September 17, 2020
    Inventors: Branden Moriarity, Beau Webber, Modassir Choudhry, Steven A. Rosenberg, Douglas C. Palmer, Nicholas P. Restifo
  • T CELL RECEPTORS RECOGNIZING MUTATED P53
    Publication number: 20200277352
    Abstract: Disclosed is an isolated or purified T cell receptor (TCR) having antigenic specificity for mutated human p53. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
    Type: Application
    Filed: September 17, 2018
    Publication date: September 3, 2020
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Drew C. Deniger, Steven A. Rosenberg, Anna Pasetto, Rami Yoseph, Winifred M. Lo, Yong-Chen Lu, Maria R. Parkhurst, Paul F. Robbins, Parisa Malekzadeh
  • T CELL RECEPTORS RECOGNIZING MHC CLASS II-RESTRICTED MAGE-A3
    Publication number: 20200270329
    Abstract: The invention provides an isolated or purified T-cell receptor (TCR) having antigenic specificity for MHC Class II-restricted MAGE-A3. The invention further provides related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells. Further provided by the invention are antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a mammal are further provided by the invention.
    Type: Application
    Filed: March 9, 2020
    Publication date: August 27, 2020
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Paul F. Robbins, Steven A. Rosenberg, Xin Yao
  • METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION
    Publication number: 20200254018
    Abstract: Disclosed are methods of selectively expanding a number of T cells. The methods may comprise: modifying human T cells to express a TCR, wherein the TCR comprises a murine constant region; producing a population of cells comprising a number of human T cells expressing the TCR and a number of human T cells not expressing the TCR; and culturing the population of cells in the presence of (i) irradiated feeder cells, (ii) one or more cytokines, and (iii) an antibody, or an antigen-binding portion thereof, wherein the antibody has antigenic specificity for the murine constant region of the TCR, so as to selectively expand the number of T cells expressing the TCR over the number of T cells not expressing the TCR. Also disclosed are related populations of cells, pharmaceutical compositions, and methods of treating or preventing cancer.
    Type: Application
    Filed: September 24, 2018
    Publication date: August 13, 2020
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Drew C. Deniger, Steven A. Feldman, Steven A. Rosenberg
  • ANTI-KRAS-G12D T CELL RECEPTORS
    Publication number: 20200247869
    Abstract: Disclosed is an isolated or purified T cell receptor (TCR) having antigenic specificity for mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) presented in the context of an HLA-Cw*0802 molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
    Type: Application
    Filed: April 2, 2020
    Publication date: August 6, 2020
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Eric Tran, Yong-Chen Lu, Anna Pasetto, Paul F. Robbins, Steven A. Rosenberg, Zhili Zheng
  • Methods of producing enriched populations of tumor reactive T cells from peripheral blood
    Patent number: 10716809
    Abstract: Methods of obtaining a cell population enriched for tumor-reactive T cells, the method comprising: (a) obtaining a bulk population of peripheral blood mononuclear cells (PBMCs) from a sample of peripheral blood; (b) specifically selecting CD8+ T cells that also express PD-1 and/or TIM-3 from the bulk population; and (c) separating the cells selected in (b) from unselected cells to obtain a cell population enriched for tumor-reactive T cells are disclosed. Related methods of administering a cell population enriched for tumor-reactive T cells to a mammal, methods of obtaining a pharmaceutical composition comprising a cell population enriched for tumor-reactive T cells, and isolated or purified cell populations are also disclosed.
    Type: Grant
    Filed: November 15, 2017
    Date of Patent: July 21, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Alena Gros, Steven A. Rosenberg
  • Methods of Preparing T Cells for T Cell Therapy
    Publication number: 20200206265
    Abstract: Provided herein are methods for delaying or inhibiting T cell maturation or differentiation in vitro for a T cell therapy, comprising contacting one or more T cells from a subject in need of a T cell therapy with an AKT inhibitor and at least one of exogenous Interleukin-7 (IL-7) and exogenous Interleukin-15 (IL-15), wherein the resulting T cells exhibit delayed maturation or differentiation. In some embodiments, the method further comprises administering the one or more T cells to a subject in need of a T cell therapy.
    Type: Application
    Filed: August 6, 2019
    Publication date: July 2, 2020
    Inventors: Arianne PEREZ, Marianna Sabatino, Steven A. Rosenberg, Nicholas P. Restifo
  • ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR VARIANT III CHIMERIC ANTIGEN RECEPTORS AND USE OF SAME FOR THE TREATMENT OF CANCER
    Publication number: 20200157241
    Abstract: The invention provides chimeric antigen receptors (CARs) comprising an antigen binding domain of human antibody 139, an extracellular hinge domain, a transmembrane domain, and an intracellular domain T cell receptor signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a host are also disclosed.
    Type: Application
    Filed: January 24, 2020
    Publication date: May 21, 2020
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Richard A. Morgan, Steven A. Rosenberg
  • WRITING ELECTRONIC PAPER
    Publication number: 20200147978
    Abstract: Embodiments of the present invention are directed to systems and methods for writing on electronic paper (“e-paper”) and display platforms implemented with e-paper. In one aspect, a system for writing information to electronic paper includes a writing module and an erasing unit connected to the writing module. The erasing unit is configured to erase information stored in the electronic paper. The system also includes a writing unit connected to the writing module and is configured to write information to the electronic paper. Information is written to the electronic paper by orienting the writing module so that the electronic paper passes the erasing unit prior to passing the writing unit.
    Type: Application
    Filed: January 15, 2020
    Publication date: May 14, 2020
    Applicant: HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P.
    Inventors: Omer Gila, Napoleon J. Leoni, Steven Rosenberg, Henryk Birecki
  • T CELL RECEPTORS RECOGNIZING HLA-CW8 RESTRICTED MUTATED KRAS
    Publication number: 20200148739
    Abstract: Disclosed is an isolated or purified T cell receptor (TCR) having antigenic specificity for mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) presented in the context of an HLA-Cw*0802 molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
    Type: Application
    Filed: January 10, 2020
    Publication date: May 14, 2020
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Eric Tran, Yong-Chen Lu, Steven A. Rosenberg
  • T cell receptors recognizing MHC class II-restricted MAGE-A3
    Patent number: 10611815
    Abstract: The invention provides an isolated or purified T-cell receptor (TCR) having antigenic specificity for MHC Class II-restricted MAGE-A3. The invention further provides related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells. Further provided by the invention are antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a mammal are further provided by the invention.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: April 7, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Paul F. Robbins, Steven A. Rosenberg, Xin Yao
  • Anti-KRAS-G12D T cell receptors
    Patent number: 10611816
    Abstract: Disclosed is an isolated or purified T cell receptor (TCR) having antigenic specificity for mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) presented in the context of an HLA-Cw*0802 molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: April 7, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Eric Tran, Yong-Chen Lu, Anna Pasetto, Paul F. Robbins, Steven A. Rosenberg, Zhili Zheng
  • METHODS OF ISOLATING T CELLS AND T CELL RECEPTORS HAVING ANTIGENIC SPECIFICITY FOR A CANCER-SPECIFIC MUTATION FROM PERIPHERAL BLOOD
    Publication number: 20200095548
    Abstract: Disclosed are methods of isolating T cells and TCRs having antigenic specificity for a mutated amino acid sequence encoded by a cancer-specific mutation. Also disclosed are related methods of preparing a population of cells, populations of cells, TCRs, pharmaceutical compositions, and methods of treating or preventing cancer.
    Type: Application
    Filed: December 11, 2019
    Publication date: March 26, 2020
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Alena Gros, Steven A. Rosenberg
  • Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer
    Patent number: 10570214
    Abstract: The invention provides chimeric antigen receptors (CARs) comprising an antigen binding domain of human antibody 139, an extracellular hinge domain, a transmembrane domain, and an intracellular domain T cell receptor signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a host are also disclosed.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: February 25, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Richard A. Morgan, Steven A. Rosenberg
  • METHODS OF ISOLATING NEOANTIGEN-SPECIFIC T CELL RECEPTOR SEQUENCES
    Publication number: 20200056237
    Abstract: Disclosed are methods of isolating paired T cell receptor (TCR) alpha and beta chain sequences, or an antigen-binding portion thereof. Also disclosed are methods of automatically identifying the TCR alpha and beta chain V segment sequences and CDR3 sequences of a TCR having antigenic specificity for a mutated amino acid sequence encoded by a cancer-specific mutation. Methods of preparing a population of cells that express paired TCR alpha and beta chain sequences, or an antigen-binding portion thereof, are also disclosed. Isolated pairs of TCR alpha and beta chain sequences and isolated populations of cells prepared by the methods are also disclosed.
    Type: Application
    Filed: March 28, 2018
    Publication date: February 20, 2020
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Yong-Chen Lu, Peter Fitzgerald, Zhili Zheng, Steven A. Rosenberg
  • T cell receptors recognizing HLA-Cw8 restricted mutated KRAS
    Patent number: 10556940
    Abstract: Disclosed is an isolated or purified T cell receptor (TCR) having antigenic specificity for mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) presented in the context of an HLA-Cw*0802 molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: February 11, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Eric Tran, Yong-Chen Lu, Steven A. Rosenberg
  • Methods of isolating T cells and T cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood
    Patent number: 10544392
    Abstract: Disclosed are methods of isolating T cells and TCRs having antigenic specificity for a mutated amino acid sequence encoded by a cancer-specific mutation. Also disclosed are related methods of preparing a population of cells, populations of cells, TCRs, pharmaceutical compositions, and methods of treating or preventing cancer.
    Type: Grant
    Filed: April 29, 2016
    Date of Patent: January 28, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Alena Gros, Steven A. Rosenberg